Search Results 811-820 of 19211 for hemoglobin

1. A Study of the Safety and Effectiveness of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unremoveable Malignant Pleural Mesothelioma - Mayo Clinic

   Hemoglobin greater than or equal to 9 g/dL; Serum bilirubin less than or equal to 1.5 x upper limit of normal (ULN). Participants with serum bilirubin ...

2. Study of Determine the Safety and Effectiveness of SHP647 as Maintenance Therapy in Subjects with Moderate-to-Severe Crohn's Disease - Mayo Clinic

   Hemoglobin level ≤ 80 g/L (8.0 g/dL);; Platelet count ≤ 100 × 109/L (100,000 cells/mm^3) or ≥ 1000 × 109/L (1,000,000 cells/mm^3)*;; White blood cell count ...

3. Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis - Mayo Clinic

   Hemoglobin ≥ 11.0 g/dL; Total bilirubin ≤ 1.5 x upper limit of normal (ULN) unless due to Gilbert's disease; if total bilirubin is > 1.5 x ULN, a direct ...

4. A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment - Mayo Clinic

   Hemoglobin < 8 g/dL;; Platelets < 100,000/μL;; Positive serum pregnancy test at the Screening visit or positive urine pregnancy test at the Baseline visit ...

5. A Study in Treating Patients With Kidney Cancer Undergoing Nephrectomy Comparing PERioperative Nivolumab vs. Observation - Mayo Clinic

   Hemoglobin >= 9.0 g/dL, within 4 weeks of randomization. Serum creatinine =< 1.5 x upper limit of normal (ULN) or calculated creatinine clearance (CrCl) ...

6. Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment - Mayo Clinic

   Hemoglobin ≥9 g/dL;; Serum creatinine ≤1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥50 mL/min using Cockcroft-Gault equation ...

7. Impact Of Estradiol Addback - Mayo Clinic

   ... hemoglobin <12.0 gm/dL; Drug or alcohol abuse, psychosis, depression, mania or severe anxiety;; Acute or chronic organ-system disease;; Endocrinopathy, other ...

8. A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma - Mayo Clinic

   Hemoglobin ≥ 9 g/dL;; ANC ≥ 1.5 x 10^9/L;; Platelet count ≥ 75 x 10^9/L. Serum creatinine ≥ ULN; or estimated creatinine clearance ≥ 50 mL/min by ...

9. A Study to Evaluate Intravenous Iloprost in Subjects with Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis - Mayo Clinic

   ... hemoglobin). Subjects with scleroderma renal crisis within 6 months of screening. Subjects with a concomitant life-threatening disease with a life ...

10. Subarachnoid hemorrhage - Doctors and departments - Mayo Clinic

    Find out more about diagnosis and treatment options for this bleeding in the brain.